Targeted Sequencing and Resequencing Market Size & Growth Forecast 2027–2036, By Segments (Technology, End-use, Type, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Targeted Sequencing and Resequencing Market size was assessed at USD 11.3 billion in 2026 and is poised to grow at a 21.47% CAGR between 2027 and 2036, exceeding USD 79.03 billion by 2036. The industry revenue for 2027 is estimated at USD 13.34 billion.
Get more details on this report
Request Free Sample ReportTargeted Sequencing and Resequencing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 52.69% share in 2026, supported by established genomics infrastructure, widespread clinical adoption, and strong demand from pharmaceutical, biotechnology, and academic organizations.
- Asia Pacific is projected to expand at a 24.09% CAGR as precision medicine initiatives, laboratory capacity expansion, and broader sequencing adoption increase demand across healthcare and research settings.
Segment Momentum
- Sequencing held a 68.68% market share in 2026 because it serves as the primary technology for generating genomic data, supporting baseline genetic profiling, mutation detection, and first-pass analyses across targeted applications.
- Hospitals & clinics are expanding fastest as targeted genomic testing becomes part of routine patient care, with demand driven by actionable results, shorter reporting times, and stronger integration into diagnosis and treatment decisions.
Market Expansion Drivers
- Expanding precision oncology driving targeted genetic testing adoption in clinical workflows.
- Increasing R&D in genomics accelerating biomarker discovery and disease research applications.
- Declining sequencing costs improving accessibility of targeted NGS platforms in diagnostics.
Leading Market Participants
- Key companies in the targeted sequencing and resequencing market include Illumina, Inc. (United States), Agilent Technologies, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Oxford Nanopore Technologies plc (United Kingdom), Pacific Biosciences of California, Inc. (United States), QIAGEN N.V. (Germany), BGI Genomics Co., Ltd. (China), PerkinElmer Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 11.3 billion
- 2027 Estimated Market Size: USD 13.34 billion.
- Projected Market Size: USD 79.03 billion by 2036
- Growth Forecast: 21.47% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Sequencing (Technology) | Academic Research (End-use) | DNA-based Targeted Sequencing (Type) | Clinical Application (Application)
- Emerging Opportunity Segment: Re-sequencing (Technology) | Hospitals & Clinics (End-use) | RNA-based Targeted Sequencing (Type) | Drug Development (Application)
Market Growth Drivers and Industry Trends
Expanding precision oncology driving targeted genetic testing adoption in clinical workflows
The targeted sequencing and resequencing market is being strengthened by the expansion of precision oncology, where molecular information is increasingly used to guide diagnosis, treatment selection, and disease monitoring. Targeted genetic testing enables clinicians to examine specific genes and genomic regions associated with cancers, helping identify actionable mutations and molecular markers relevant to individual patients. As oncology workflows place greater emphasis on matching therapies with tumor-specific characteristics, targeted sequencing can provide focused genomic information without requiring analysis of an entire genome. Its compatibility with clinical testing workflows and ability to support biomarker-based decision-making are encouraging broader integration of targeted genomic analysis in cancer care.
Increasing R&D in genomics accelerating biomarker discovery and disease research applications
Growing investment in genomic research is creating broader opportunities for the targeted sequencing and resequencing market across biomarker discovery and disease investigation. Researchers can use targeted approaches to examine selected genomic regions associated with disease mechanisms, inherited conditions, therapeutic response, and other biological characteristics, making these technologies useful for focused research programs. Increasing genomic R&D is also generating demand for tools capable of validating previously identified genetic signals and investigating clinically relevant variants across different populations or disease models. The ability to concentrate sequencing resources on biologically important regions supports efficient experimental design and facilitates the integration of genomic findings into translational research.
Declining sequencing costs improving accessibility of targeted NGS platforms in diagnostics
Lower sequencing costs are making next-generation sequencing technologies more accessible to diagnostic laboratories and healthcare providers, supporting wider adoption of targeted testing. This trend will boost the targeted sequencing and resequencing market by reducing financial barriers associated with genomic analysis and making targeted NGS approaches more practical for routine diagnostic applications. Targeted platforms can focus analytical resources on genes or genomic regions relevant to a particular condition, which can also simplify testing requirements compared with broader sequencing strategies. Improved affordability combined with advancing sequencing workflows is enabling more laboratories to incorporate genomic testing into diagnostic services, including applications involving hereditary disorders, cancer-associated variants, and other molecularly defined conditions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding precision oncology driving targeted genetic testing adoption in clinical workflows | 2.80% | High | North America, Europe | High | Near Term |
| Increasing R&D in genomics accelerating biomarker discovery and disease research applications | 2.40% | High | North America, Asia Pacific | High | Mid Term |
| Declining sequencing costs improving accessibility of targeted NGS platforms in diagnostics | 2.10% | Moderate | Global | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The targeted sequencing and resequencing market in North America accounted for the largest share of 52.69% in 2026, driven by advanced genomic research infrastructure, strong adoption of precision medicine, and established capabilities in molecular diagnostics. Increasing demand for targeted genetic analysis is supporting applications across research, clinical investigation, and disease-related studies. The region's sophisticated healthcare and biotechnology ecosystem, combined with continued investment in genomic technologies, is reinforcing demand for efficient and precise sequencing solutions.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, supported by expanding healthcare infrastructure, rising genomic research activity, and increasing adoption of precision-focused diagnostic approaches. Greater investment in biotechnology capabilities is improving access to sequencing technologies, while growing awareness of genomic applications is broadening demand across research and healthcare settings. Regional modernization of laboratory infrastructure is further creating opportunities for targeted sequencing and resequencing technologies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany emphasizes validated targeted sequencing workflows for molecular diagnostics and translational research. German laboratories increasingly adopt standardized sequencing solutions that improve reproducibility while meeting stringent clinical and regulatory expectations.
France 🇫🇷
Translational Research SupportFrance advances targeted sequencing through collaborative research programs linking academic institutions, hospitals, and biotechnology companies. French laboratories focus on generating clinically relevant genomic insights that improve disease characterization and therapeutic decision-making.
Italy 🇮🇹
Molecular Testing AdoptionItaly continues expanding targeted sequencing within hospital laboratories and specialized diagnostic centers. Italian healthcare providers prioritize cost-effective genomic workflows that strengthen molecular testing capabilities across oncology and inherited disease applications.
Japan 🇯🇵
Advanced Diagnostic IntegrationJapan integrates targeted sequencing into cancer care, rare disease research, and precision diagnostics. Japanese healthcare organizations prioritize reliable sequencing technologies that enhance diagnostic accuracy and enable efficient genomic data analysis.
South Korea 🇰🇷
Genomic Innovation EcosystemSouth Korea strengthens targeted sequencing capabilities through investments in biotechnology, precision healthcare, and genomic research. Local organizations increasingly deploy high-throughput sequencing platforms to accelerate clinical applications and biomedical discoveries.
United States 🇺🇸
Precision Genomics ExpansionThe U.S. continues expanding targeted sequencing and resequencing across precision medicine, oncology, and clinical diagnostics. Healthcare providers and research institutions prioritize scalable sequencing platforms that improve genomic interpretation and support personalized treatment decisions.
Segment Leadership and Growth Trends
Targeted Sequencing and Resequencing Market Share (%), by Technology, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnology Segment Analysis: Sequencing (Largest Segment) vs Re-sequencing (Fastest-Growing Segment)
The sequencing segment represented the largest share of the targeted sequencing and resequencing market at 68.68% in 2026, reflecting widespread use of targeted sequencing to examine selected genomic regions relevant to disease research, diagnostics, and precision medicine. By concentrating analysis on clinically or biologically important regions, targeted sequencing can provide efficient genomic information while reducing unnecessary sequencing of unrelated areas. Growing adoption of genomic testing and increasing demand for focused molecular analysis are supporting the segment's established position.
Re-sequencing is expanding more rapidly as researchers and healthcare professionals increasingly seek to compare genomic variations, identify mutations, and characterize genetic differences across samples. Advances in sequencing technologies and growing interest in personalized medicine are creating broader applications for re-sequencing in disease research and genomic analysis. The increasing need to understand genetic variation and refine molecular insights is supporting faster adoption of re-sequencing approaches.
End-use Segment Analysis: Academic Research (Largest Segment) vs Hospitals & Clinics (Fastest-Growing Segment)
Academic research accounted for the largest share of the targeted sequencing and resequencing market at 52.86% in 2026, driven by extensive use of genomic technologies in basic research, disease studies, biomarker discovery, and investigation of genetic variation. Academic institutions use targeted sequencing to generate focused genomic datasets while supporting research into disease mechanisms and biological processes. Expanding genomic research programs and increasing availability of advanced sequencing technologies continue to support demand from academic users.
Hospitals & clinics are growing at a faster pace as genomic analysis becomes increasingly integrated into clinical decision-making, disease diagnosis, and personalized treatment strategies. Targeted sequencing can provide focused information relevant to specific diseases or genetic markers, supporting more informed patient management. Increasing adoption of precision medicine, growing clinical interest in molecular diagnostics, and the integration of genomic testing into healthcare workflows are strengthening demand from hospitals and clinics.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Sequencing, Re-sequencing | Sequencing | Re-sequencing |
| End-use | Hospitals & Clinics, Academic Research, Others | Academic Research | Hospitals & Clinics |
| Type | DNA-based Targeted Sequencing, RNA-based Targeted Sequencing | DNA-based Targeted Sequencing | RNA-based Targeted Sequencing |
| Application | Clinical Application, Plant and Animal Sciences, Drug Development, Others | Clinical Application | Drug Development |
Competitive Landscape and Market Positioning
Key companies in the targeted sequencing and resequencing market:
1. Illumina Inc. (United States)
2. Agilent Technologies Inc. (United States)
3. F. Hoffmann-La Roche Ltd. (Switzerland)
4. Thermo Fisher Scientific Inc. (United States)
5. Bio-Rad Laboratories Inc. (United States)
6. Oxford Nanopore Technologies plc (United Kingdom)
7. Pacific Biosciences of California Inc. (United States)
8. QIAGEN N.V. (Germany)
9. BGI Genomics Co. Ltd. (China)
10. PerkinElmer Inc. (United States)
Continuous innovation in genomic analysis is driving the targeted sequencing and resequencing market, with advanced sequencing technologies and AI-assisted data interpretation improving analytical precision. Strong research investments are expanding applications in clinical diagnostics, oncology, and genetic research.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Illumina Inc. (United States) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Oxford Nanopore Technologies plc (United Kingdom) | |||||||
| Pacific Biosciences of California Inc. (United States) | |||||||
| QIAGEN N.V. (Germany) | |||||||
| BGI Genomics Co. Ltd. (China) | |||||||
| PerkinElmer Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Illumina, Inc. | Jun-25 | Illumina, Inc. acquired SomaLogic for up to USD 425 million to expand its presence into proteomics through the SomaScan platform. The transaction broadened Illumina’s multi-omics capabilities, enabling integration of protein-level data with sequencing-based genomic analysis for enhanced biomarker discovery applications. |
| Illumina, Inc. | Apr-25 | Illumina, Inc. entered a strategic partnership with Tempus AI to accelerate adoption of AI-driven next-generation sequencing tests. The collaboration focused on integrating computational capabilities with sequencing workflows to improve diagnostic development efficiency and support broader clinical utilization of genomic testing platforms. |
| GeneDx | Apr-25 | GeneDx acquired Fabric Genomics to scale decentralized AI-powered genomic testing capabilities. The acquisition strengthened GeneDx’s precision diagnostics infrastructure and expanded its ability to deliver distributed sequencing and interpretation solutions across clinical genomics applications. |
| QIAGEN N.V. | Mar-22 | QIAGEN N.V. collaborated with NHS England and NHS Improvement to deploy its Human Gene Mutation Database for interpretation of next-generation sequencing data in inherited diseases. The initiative supported improved clinical interpretation workflows and reinforced QIAGEN’s role in enabling genomic diagnostics adoption within healthcare systems. |
| Illumina, Inc. | Sep-21 | Illumina, Inc. announced expansion plans for its genomics operations in Latin America through the establishment of local entities in Colombia and Mexico. The initiative was aimed at strengthening regional customer engagement and expanding access to sequencing technologies across emerging healthcare and research markets. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Targeted Sequencing and Resequencing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sequencing Platform | Short-Read Sequencing, Long-Read Sequencing |
| Sample Type | Blood & Plasma, Tissue Samples, Saliva & Buccal Samples, Other Biological Samples |
| Product & Service Type | Kits & Reagents, Instruments & Consumables, Bioinformatics & Data Analysis Services, Sequencing Services |
Targeted Sequencing and Resequencing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Precision Medicine Adoption Landscape |
|
| Companion Diagnostics Commercialization Outlook |
|
| Biopharma Biomarker Development Pipeline Analysis |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the targeted sequencing and resequencing market?
What are the growth projections for the targeted sequencing and resequencing industry?
How is the shift toward precision oncology influencing adoption of targeted sequencing in clinical decision-making workflows?
What is driving the increasing relevance of re-sequencing compared with traditional sequencing approaches?
Why is Sequencing the largest technology segment in the targeted sequencing and resequencing market?
Why are Hospitals & Clinics the fastest-growing end-use segment in the targeted sequencing and resequencing market?
What factors support North America's leadership in the targeted sequencing and resequencing market?
Why is Asia Pacific emerging as the fastest-growing regional market?
Who are the leading players in the targeted sequencing and resequencing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization